MH Eckman, J Rosand, SM Greenberg, BF … - Annals of Internal Medicine, 2009 - Am Coll Physicians Background: Variants in genes involved in warfarin metabolism and sensitivity
affect individual warfarin requirements and the risk for bleeding. Testing for
these variant alleles might allow more personalized dosing of warfarin ... Cited by 28 - Related articles - All 6 versions
- ►nih.gov KN Kangelaris, S Bent, RL Nussbaum, DA … - Journal of general internal medicine, 2009 - Springer Page 1. REVIEWS Genetic Testing Before Anticoagulation? A Systematic Review
of Pharmacogenetic Dosing of Warfarin Kirsten Neudoerffer ... Cited by 9 - Related articles - All 8 versions
M Beinema, JR Brouwers, T Schalekamp, B … - Thrombosis and haemostasis, 2008 - ncbi.nlm.nih.gov Coumarin oral anticoagulant drugs have proven to be effective for the prevention
of thromboembolic events. World-wide, warfarin is the most prescribed drug. In
Europe, acenocoumarol and phenprocoumon are also administered. Yet it has ... Cited by 8 - Related articles - All 2 versions
Y Caraco, S Blotnick, M Muszkat - Clinical Pharmacology & Therapeutics, 2007 - nature.com Warfarin anticoagulation effect is characterized by marked variability, some of
which has been attributed to CYP2C9 polymorphisms. This study prospectively
examines whether a priori knowledge of CYP2C9 genotype may improve warfarin ... Cited by 83 - Related articles - All 4 versions
- ►hematologylibrary.org M Wadelius, LY Chen, JD Lindh, N Eriksson, … - Blood, 2009 - bloodjournal.hematologylibrary.org Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase
(VKORC1) are known to influence warfarin dose, but the effect of other genes has
not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate ... Cited by 48 - Related articles - All 6 versions
PA Ioannidis John - Annals of Internal Medicine, 2009 - citation.nstl.gov.cn Genetic epidemiology has identified many common genetic variants that are
associated with common diseases, and the list is growing monthly. This success
has boosted expectations for personalized genetic prediction. According to ... Cited by 9 - Related articles - Cached - All 2 versions
- ►clinchem.org Y Zhu, M Shennan, KK Reynolds, NA Johnson, … - Clinical Chemistry, 2007 - Am Assoc Clin Chem Background: CYP2C9 polymorphisms are associated with decreased S-warfarin
clearance and lower maintenance dosage. Decreased expression of VKORC1 resulting
from the –1639G>A substitution has also been implicated in lower warfarin ... Cited by 55 - Related articles - All 8 versions
MS Wen, MTM Lee, JJ Chen, HP Chuang, LS … - Clinical Pharmacology & Therapeutics, 2008 - nature.com Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with
warfarin dose requirements and could be used to predict warfarin dose. We
conducted a prospective study in which warfarin dose was prescribed based ... Cited by 23 - Related articles - All 3 versions
D Melzer, S Hogarth, K Liddell, T Ling, S … - British Medical Journal, 2008 - bmj.com Genome-wide studies have recently identified many new variants associated with
common diseases. Findings point mainly to sets of variants with modest effects,
with many more markers still to be discovered. Some variants are shedding ... Cited by 12 - Related articles - BL Direct - All 4 versions
LM Meckley, AK Wittkowsky, MJ Rieder, AE … - Thrombosis and haemostasis, 2008 - ncbi.nlm.nih.gov The objective of this study was to assess the relative influence of VKORC1 and
CYP2C9 genetic variants on several clinical outcomes related to warfarin
treatment. We conducted a retrospective cohort analysis of 172 ... Cited by 13 - Related articles - All 3 versions
